4. Glycemic response: an increase in plasma glucose (PG) of \>30 mg/dL (1.7 mmol/L) after 1 mg IV or intramuscular (IM) glucagon administration
Male or female, age ≥7 days and \<12 months at screening
Body weight of ≥2.0 kg (4.4 lbs.)
Continuous IV glucose requirement to prevent hypoglycemia
You may not be if
Is suspected of having a transient form of CHI (e.g., transient hyperinsulinism due to maternal diabetes or perinatal stress)
Was born preterm below 34 weeks of gestational age
Presence of hypertension or hypotension, including circulatory instability requiring supportive medication or presence of pheochromocytoma
Known or suspected presence of severe brain damage
Evidence of metabolic, endocrine, or syndromic causes of hypoglycemia not due to hyperinsulinism
Use of systemic corticosteroids, e.g., hydrocortisone \>20 mg/m\^2 body surface area or equivalent within 5 days before screening
Prior use of lanreotide, sirolimus (mechanistic target of rapamycin \[mTOR\] inhibitors), anti-inflammatory biological agents, or other immune modulating agents. Prior use of octreotide is allowed after a minimum of 48 hour washout before randomization.
Any clinically significant abnormality identified on echocardiogram that in the opinion of the investigator would affect the subject's ability to participate in the trial
Any recognized clotting or bleeding disorder
The use of prescription or non-prescription medications known to cause QT prolongation
